Navigation Links
Delcath to Present at the 30th Annual Canaccord Global Growth Conference
Date:8/4/2010

ystemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, market acceptance and the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenu
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... and NOTTINGHAM, England , ... CBRX ) today announced that its subsidiary, Molecular ... Clinical Trials platform at the annual CPhI/ICSE Worldwide event ... aims to support companies with the rapid development of ... new enabling technologies screening platform, which incorporates the company,s ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
(Date:10/1/2014)... eye, the brain of a rat and a robot ... a QUT leading robotics researcher. , Dr Michael ... new study uses new computer algorithms to enable robots ... , "This is a very Frankenstein type of project," ... a thing together because we,re taking the eyes of ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... , , , ... BMR ), The Leading Provider of Real Estate to the Life Science ... ring The Closing Bell(R) at the New York Stock Exchange on Thursday, ... anniversary of the company,s initial public offering. The ceremony will take place ...
... Tinnitus Sufferer ... ... of a deep-sleep to a high pitch ringing sound in your ear, or constantly hearing ... reality for millions of men and women who suffer from the medical condition tinnitus, often ...
... ... marketplace. , ... FL (PRWEB) August 6, 2009 -- Because prices and benefits for Medicare Supplement (Medigap) ... rates offered by GetOnlineQuotes.com are an affordable and viable option for those 65 and ...
... August 6, 2009 Comprehensive health reform proposals now before ... young adults ages 19-29 gain coverage, and such reforms ... coverage would not lose it, according to a new ... Americans through expansions in Medicaid and a health insurance ...
... Addison, TEXAS, Aug. 5 U L URU ... today announced that it has scheduled a conference call to discuss the second ... on Monday, August 17, 2009 at 9:00 a.m. Eastern Time. , , ... international callers dial (850) 429-1388 (access code 23453#) five to ten minutes prior ...
... , , MENLO PARK, Calif., ... announced that it has provided written notice to The NASDAQ Stock ... stock from the NASDAQ Global Market. The Company currently anticipates that, ... the Securities and Exchange Commission and NASDAQ a Form 25 relating ...
Cached Medicine News:Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 2Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 3Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 4Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 5Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 6Health News:BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company 7Health News:Lipo-Flavonoid Launches New Video Testimonial 2Health News:Lipo-Flavonoid Launches New Video Testimonial 3Health News:GetOnlineQuotes.com to Offer AARP/United Healthcare Medicare Supplement Insurance to Florida Residents 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 3Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update 2Health News:XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: